To the Editor

The new coronavirus (SARS-CoV-2)[@bib0005], [@bib0010] has demonstrated the heavy health and socioeconomic impact that an epidemic can have worldwide. In the face of such pandemics, governments and health authorities must act quickly[@bib0015] and implement policies that aim to limit the transmission of the virus, avoid the collapse of the health system, and reduce the morbidity and mortality associated with the virus - strategies all driven by the need to prioritize resources in settings where they are scarce. In this respect, supporting decision-making with the use of mathematical models can be a key factor. These tools are potentially useful for explaining and predicting the speed and manner in which the virus spreads, in order to support health planning, identify and stratify patient risk, and establish prognosis from electronic records.

A crucial consideration in the area of mathematical modeling is that the data collected are usually observational in nature. This may lead to significant bias in the results obtained from the systematic application of conventional statistical techniques.[@bib0020] Another important factor is incomplete information,[@bib0025] such as censored and lost data. As no diagnostic tests are performed in many cases, it is impossible to know whether or not they are infected. In addition, endpoints such as recovery or death have not yet been reached during the course of the study. Moreover, patients with no symptoms or mild symptoms are the least likely to visit a doctor or even have a diagnostic test. Again, ignoring the effects of missing or censored data may confer significant bias on the conclusions reached.[@bib0025]

From a statistical point of view, the study design may be more important than the amount of data collected. However, in a health emergency, governments may be overwhelmed and data may be collected from severe cases only. To determine the actual extent of the pandemic, random population sampling is necessary. A clear exception to this SARS-CoV-2 crisis is the case of South Korea and Singapore, where population tests were conducted systematically, allowing outbreaks of infection to be isolated more quickly, to the extent that the effects of the virus were mitigated more quickly than in other countries.

From an epidemiological point of view, it is important to highlight the need to identify variables that indicate patient risk and prognosis. The most popular indicator is undoubtedly the mortality risk, which measures the likelihood that a patient will die if he or she has the disease. Precise estimations are not simple, and as indicated above, given the observational nature of the recorded data, the presence of biases is customary. According to Lipsitch et al.,[@bib0030] biases occur because of a delay in recording information or because there is a preponderance of patients at higher risk in the database. A potential solution to this problem in the analyses is to stratify patients into different groups based on their severity and prognosis. The use of specific techniques to manage causal inference or missing data, such as the Propensity Score or doubly robust estimators, is also recommended.[@bib0035] This approach can improve statistical inference drawn from patients belonging to each stratum.

The large discrepancies in the proportion of symptomatic patients and the mortality risk associated with SARS-CoV-2 underline the need to adopt these approaches. On March 5, 2020, the percentage of asymptomatic patients reported by the European Center for Disease Prevention and Control was 80%. However, in a study of patients from the Diamond Princess cruise ship, this figure was 20%.[@bib0045] In the latter case, the study sample comprised a greater proportion of older patients with a higher probability of presenting symptoms, making it difficult to extrapolate the conclusions to the general population. Similarly, the fatality rate varies significantly (estimates range between 0.4% and 15%[@bib0050]), partially due to the problems mentioned. The precise characterization of these variables based on the epidemiological profiles of the population is essential to understand the transmission mechanisms of the virus[@bib0055] and predict future care demands.

A basic criticism of epidemic modelling is that parameters are frequently adjusted according to government-provided statistics on infected subjects, despite the fact that very few countries can provide clear evidence that these figures reflect the real situation, given the lack of knowledge about the percentage of asymptomatic patients and lack of overall testing among the population. In fact, asymptomatic patients may be the main transmitters of the virus.[@bib0055]

Mathematical models can be an important tool for anticipating future developments and supporting decision-making. However, if data are inaccurate and specific techniques to correct the observational nature of the recorded data are not used, conclusions may be biased. In this regard, all relevant institutions should make an effort and openly provide high-quality data,[@bib0060] so that scientists can find the solutions most beneficial to society. Simultaneously, in the current era of big data,[@bib0065] collaboration between different stakeholders (health management, care, research, etc.) is essential. The use of big data would facilitate the construction of more complex models that can take advantage of all data recorded from individual patient monitoring[@bib0070] and in this way provide more agile responses to current epidemics.[@bib0075]
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